ChemoCentryx reported a GAAP loss of $38.608 million for the 3 months of 2022, up 29.9% from $29.711 million in the prior year. Revenue decreased 47.3% to $5.459 million from $10.353 million a year earlier.
ChemoCentryx reported a GAAP loss of $38.608 million for the 3 months of 2022, up 29.9% from $29.711 million in the prior year. Revenue decreased 47.3% to $5.459 million from $10.353 million a year earlier. 
ir.chemocentryx.com
English (US) 